81945-13-3

Usage

Uses

Used in Pharmaceutical Industry:
1H-Inden-1-one,4-bromo-2,3-dihydro-7-hydroxyis used as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its unique structure, including the presence of a bromine atom and a hydroxyl group, allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
1H-Inden-1-one,4-bromo-2,3-dihydro-7-hydroxyserves as a key intermediate in the synthesis of other organic compounds. Its reactive functional groups, such as the ketone and hydroxyl group, can be further modified or used in reactions to produce a wide range of chemical products, including specialty chemicals, agrochemicals, and other pharmaceuticals.

Upstream product

• 500693-84-5 4-bromophenyl 3-chloropropanoate 
• 106-41-2 4-bromo-phenol 
• 50663-21-3 (para-bromophenyl)-2-propenoate 

Relevant academic research and scientific papers

METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2-ALPHA

The present disclosure provides methods of reducing inflammation of the digestive system in a subject in need thereof, including subjects suffering from inflammatory bowel disease. Compositions for use in these methods are also provided.

COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF

The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.

COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION

The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.

AROMATIC COMPOUNDS AND USES THEREOF

Aromatic entities that modulate HIF-2α activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2α activity are described herein.

COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA

The present disclosure provides methods of treating glioblastoma multiform (GBM) in a subject in need thereof. Compositions for use in these methods are also provided.

Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors

With the goal of improving metabolic stability and further enhancing FBPase inhibitory activity, a series of tricyclic 8H-indeno[1,2-d][1,3]thiazoles was designed and synthesized with the aid of structure-based drug design. Extensive SAR studies led to th

Discovery of potent and orally active tricyclic-based FBPase inhibitors

With the aim of exploring the effect of tricyclic-based FBPase inhibitors in cells and in vivo, a series of prodrugs of tricyclic phosphonates was designed and synthesized. Introducing prodrug moieties into tricyclic-based phosphonates led to the discover

TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.